<DOC>
	<DOCNO>NCT00191412</DOCNO>
	<brief_summary>This study assess response rate , toxicity , time-to-event efficacy , potential marker pemetrexed patient liver cancer .</brief_summary>
	<brief_title>A Study Pemetrexed Treatment Patients With Advanced Metastatic Cancer Liver</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis cancer liver metastatic locally recurrent amendable curative therapy . Patient must measurable disease Patient may receive prior arterial chemoembolization , complete 8 week prior study enrollment , previous chemotherapy Prior radiation permit , must complete least 2 week prior study enrollment . Prior central nervous system metastases acceptable patient receive radiation ot brain , steroid , relate symptom . Patients prior therapy Pemetrexed . Patients history invasive malignancy , exception nonmelanoma skin cancer , exclude evidence malignancy present within last five year . Patients also exclude previous cancer treatment contraindicate protocol therapy . Patients receive radiation 25 % marrow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>